Transcutaneous Aortic Valve Implantation—A First Line Treatment for Aortic Valve Disease?
| Autor: | Robert Moss, B. Munt, Mark A. Johnson |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Aortic valve disease
Aortic valve medicine.medical_specialty business.industry medicine.disease First line treatment Stenosis Balloon expandable stent medicine.anatomical_structure Aortic valve replacement Internal medicine cardiovascular system Ventricular pressure Cardiology Medicine Radiology Nuclear Medicine and imaging Cardiology and Cardiovascular Medicine business |
| Zdroj: | Journal of the American Society of Echocardiography. 23:377-379 |
| ISSN: | 0894-7317 |
| DOI: | 10.1016/j.echo.2010.02.017 |
| Popis: | Transcutaneous aortic valve implantation (TAVI) is rapidly gaining acceptance as a viable alternative to open-heart surgery aortic valve replacement (SAVR) in high-risk surgical candidates with aortic stenosis. To date, there have been reports on the procedural success, early mortality, and short-term and intermediate-term clinical outcomes, but there are limited data on long-term outcomes of TAVI. The study by Bauer et al in this issue of JASE adds to the accumulating evidence base with the echocardiographic experience of the longest follow-up after TAVI for aortic stenosis with the Sapien series of balloon expandable aortic prostheses (Edwards Lifesciences, Irvine, CA). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|